COVID-19 vaccine development tracker

vizient.

Manufacturer	Partner	Current phase	Type/ technology	Booster Shot in Development (Y/N)	Notes
NOVAVAX	Par/Endo	Phase III	Rec. Protein Nanoparticle + adjuvant		**NVX-CoV2373.** 2-dose series. Phase III clinical trial results show 96.4% efficacy against non-alpha variants and 90% efficacy against the alpha variant. Results published in the New England Journal of Medicine. (https://www.nejm.org/doi/full/10.1056/NEJMoa2107659) Vaccine will required refrigeration only. Submitted to WHO for approval in COVAX program 9/23/21. Expect EUA filing to the FDA in Q4 of 2021 and subsequent release of product in January 2022. Refrigeration only. 10 dose vial.
MODERNA		PHASE III	mRNA	Y	**mRNA-1273.** 2 dose series at 100 mcg per dose Approved with an EUA by the FDA. Booster dose approved Oct 2021. BLA submitted 8/25/21. Expect full FDA approval in Oct 2021. Filed for EUA approval for use in children ages 12-17. Vaccine stable at refrigerated temperatures of 2 to 8 degrees C for 30 days. Conducting trial for children ages 6 months to 11 years old. Children younger than 2 years may receive a 25, 50 or 100 mcg dose. Children older than 2 years may receive 50 or 100 mcg.
PFIZER	BIONTECH, ACUITAS THERAPEUTICS	PHASE III	mRNA	Y	**BNT162b2. (Comirnaty)** 2 dose series of 30 mcg per dose. Approved by the FDA 8/23/21. Booster shot is a 30 mcg dose. Applied to the FDA for an EUA approval for children ages 5-11.
J&J	Emergent Biosolutions; Merck, Takeda (for additional mfg supply)	PHASE III	ADENOVIRUS	Y	**AD26.COV2-S.** 1 dose. Approved with an EUA by the FDA. Booster dose approved for adults 18 years old or older. Booster dose to be administered at least 2 months after initial dose. Storage requirements is refrigeration only.
SANOFI PASTEUR	GlaxoSmithKline	PHASE III	Recombinant Technology + Adjuvant	Y	**SCB-2019. (Vidprevtyn)** Recombinanat protein-based vaccine based on baculovirus. Phase III began July 2021 for 37,000 patients (Age 18 or older) in multiple countries. Rolling review of data in European Union. Expect a viable vaccine for approval by Dec of 2021 under an Emergency Use Authorization (EUA).
MERCK	RIDGEBACK BIO	PHASE III	Oral Antiviral		**MK-4482**. Molnupiravir. Oral antiviral agent being developed to treat COVID-19 in patients. Clinical trial data shows a benefit to non-hospitalized patients when taken within 4 days of exposure at 800mg twice daily. Applied for EUA in Oct. 2021. FDA hearing scheduled for 11/30/21.
ASTRAZENECA	OXFORD	PHASE III	ADENOVIRUS	N	**AZD-1222.** Currently approved in the UK. No approval currently in the US. Current candidate can be stored at refrigerated temperatures for up to 3 months. Will require 2 doses approx 28 days apart.
CUREVAC	BAYER + GSK	PHASE IIb	mRNA		**CVnCoV.** The phase 2b/3 study HERALD results published in Lancet 8/31/21. Contained 40,000 participants. Vaccine will require refrigeration only. 2 dose series 4 weeks apart.
SANOFI PASTEUR	Translate Bio	Phase II	mRNA		**MRT5500.** Phase I/II trials began in March 2021 with an enrollment of 415 adults. Expected production of 90 million doses

COVID-19 vaccine development tracker

vizient.

Manufacturer	Partner	Current phase	Type/ technology	Booster Shot in Development (Y/N)	Notes
GRITSTONE ONCOLOGY		Phase I			Second-generation COVID-19 vaccine. Phase I clinical trial enrollment began (CORAL). Aim to develop a vaccine that will use the COVID-19 spike protein and additional viral epitopes offering good targets for T cell immunity.
Last Updated: 10/19/21	For inquiries, please contact pharmacyquestions@vizientinc.com				